Japan's Takeda buying US cancer drugmaker for $5.2bn (Update)

January 9, 2017

Japan's top pharmaceutical company Takeda said it is buying a US cancer drugmaker for $5.2 billion, as its top executive left the door open to more overseas acquisitions.

Takeda is paying $24 a share for Ariad Pharmaceuticals, a premium of about 75 percent over Ariad's closing price on Friday, the companies said in a joint statement on Monday.

Ariad specialises in developing therapies for patients with rare forms of chronic and acute blood cancer leukaemia, lung cancer and other rare cancers.

The deal will give the Japanese buyer Ariad's drug brigatinib, an experimental therapy being tested in lung cancer, and already-on-the-market Iclusig, which is used to treat leukaemia.

Ariad has submitted brigatinib to US drug regulators for review with the firms saying the treatment could draw annual sales of more than $1.0 billion if approved for sale.

Takeda has been looking to refill its drug pipeline after patents have expired on some of its biggest medicines.

Japanese drugmakers are facing pressure in their home market as the government tries to cut prices of many branded medicines and put a greater focus on cheaper generics to rein in its health spending.

Takeda, led by Frenchman Christophe Weber, has been actively looking overseas, including its 2011 takeover of Swiss rival Nycomed for 9.6 billion euros (then $13.6 billion).

Canada's Valeant Pharmaceuticals had been in talks to sell its Salix gastrointestinal drugs business to Takeda for about $10 billion, although the talks broke down last year reportedly because of disagreements over the price.

Takeda's Weber said "potentially" there could be more deals ahead.

"(But) we are very strategic and very disciplined buyers," he told Bloomberg News in an interview.

"We are not scared to walk away if we feel all the conditions are not there."

Explore further: Ariad suspends sales of cancer pill Iclusig

Related Stories

Ariad suspends sales of cancer pill Iclusig

October 31, 2013
Ariad Pharmaceuticals is suspending sales of its leukemia drug Iclusig because of concerns that patients could suffer from blood clots.

Lawmakers demand answers on leukemia drug price hikes

October 20, 2016
Two top lawmakers on Thursday demanded information from a drug company that has raised prices on a leukemia drug, calling increases of tens of thousands of dollars a sign the company puts profits before patients.

Ariad to relaunch leukemia drug with new warnings (Update)

December 20, 2013
Ariad Pharmaceuticals has received approval to relaunch its leukemia drug Iclusig after addressing safety concerns raised by U.S. regulators in October.

Iclusig approved for rare leukemias

December 16, 2012
(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Pfizer buying Medivation in deal valued at about $14B (Update)

August 22, 2016
Pfizer will pay about $14 billion in cash for the cancer drug company Medivation, a deal that will add the pricey late-stage prostate cancer treatment Xtandi to its oncology portfolio.

Recommended for you

In most surgery patients, length of opioid prescription, number of refills spell highest risk for misuse

January 17, 2018
The possible link between physicians' opioid prescription patterns and subsequent abuse has occupied the attention of a nation in the throes of an opioid crisis looking for ways to stem what experts have dubbed an epidemic. ...

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.